IntrinsicIntrinsic
OverviewFinancialsChartBusiness SummaryFilingsOwnershipValuation

Citius Pharmaceuticals, Inc. (CTXR)

Business Summary

Citius Pharmaceuticals, Inc. is a biopharmaceutical company based in Cranford, New Jersey, focused on developing and commercializing first-in-class critical care products, with an emphasis on oncology, anti-infectives in adjunct cancer care, and unique prescription products. The company's strategy involves targeting unmet medical needs with therapeutic products that have lower development risk, often through new formulations of previously approved drugs with existing safety and efficacy data. Citius Pharmaceuticals aims to achieve leading market positions by focusing on products with intellectual property and regulatory exclusivity protection that offer competitive advantages .

The company's core business model revolves around the development and commercialization of proprietary product candidates. As of December 2025, Citius Pharmaceuticals became a commercial company with the launch of LYMPHIR by its majority-owned subsidiary, Citius Oncology . The company generates revenue through product sales and seeks to monetize its pipeline through strategic partnerships, joint ventures, mergers, acquisitions, or licensing transactions . The primary customer segments are highly influenced by key opinion leaders and involve a relatively small number of prescribing physicians, allowing for a manageable commercialization effort .

One of Citius Pharmaceuticals' key product candidates is LYMPHIR (denileukin diftitox), an engineered IL-2 diphtheria toxin fusion protein, approved by the FDA in August 2024 for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) . LYMPHIR was launched in December 2025 by Citius Oncology, a majority-owned subsidiary in which Citius Pharma holds approximately 77.9% of outstanding common stock as of December 17, 2025 . The company estimates the addressable U.S. market for LYMPHIR to exceed $400 million . LYMPHIR's mechanism of action involves killing tumors by binding to IL-2 receptors and depleting immunosuppressive regulatory T lymphocytes (Tregs) . Preliminary results from a Phase 1 trial combining LYMPHIR with pembrolizumab in recurrent solid tumors showed an overall response rate (ORR) of 27% (4/15) and a clinical benefit rate of 33% (5/15) among evaluable patients, with a median progression-free survival (PFS) of 57 weeks for those achieving clinical benefit .

Another late-stage product candidate is Mino-Lok, a patented antibiotic lock solution designed to treat and salvage infected central venous catheters (CVCs) in patients with catheter-related bloodstream infections (CRBSIs) . Mino-Lok works by breaking down biofilm barriers, eradicating bacteria, and providing anti-clotting properties . A Phase 2b study demonstrated 100% efficacy in salvaging CVCs, comparable to removal and replacement, with no significant adverse events (SAEs) compared to an 18% SAE rate in the control group . The Phase 3 trial, which enrolled 241 patients across 34 sites in the U.S. and India, met its primary endpoint with a statistically significant improvement in time to catheter failure for Mino-Lok compared to standard-of-care antibiotic lock solution . The median time to catheter failure in the Mino-Lok arm was significantly prolonged (p ≤ 0.0006), catheter retention was achieved in 57% of Mino-Lok patients versus 38% in the control arm (p = 0.0025), and rates of clinical and microbiological failure were significantly lower in the Mino-Lok arm (p = 0.0058 and p = 0.012, respectively) . The company estimates the potential U.S. market for Mino-Lok to be approximately $500 million to $1 billion .

Halo-Lido is a topical formulation of halobetasol propionate and lidocaine intended for the treatment of hemorrhoids . There are currently no FDA-approved prescription drug products for hemorrhoids, and existing topical prescription products are available due to the DESI program without FDA-reviewed efficacy or safety data . A Phase 2b study of Halo-Lido showed that 42% of patients in the high-dose group reached a Meaningful Change Threshold (MCT) in hemorrhoidal symptoms, compared to 29% for high-dose halobetasol alone and 21% for lidocaine alone, with a statistically significant improvement over lidocaine alone (CMH test, p = 0.035) . The company believes Halo-Lido represents an attractive, low-risk product opportunity with meaningful upside potential and intends to monetize its value by seeking a strategic or financial partner .

NoveCite, a majority-owned subsidiary in which Citius Pharma owns 75% of the outstanding capital stock, is focused on developing mesenchymal stem cell therapy (NC-iMSCs) for acute respiratory conditions, with a near-term focus on Acute Respiratory Distress Syndrome (ARDS) . NC-iMSCs are described as differentiated and superior to donor-derived MSCs, offering higher potency, unlimited supply, consistent quality, and significantly higher expansion capability . Preliminary data from a proof-of-concept large animal study showed improvement in critical parameters such as oxygenation, systemic shock, and reduced lung injury . The global market for ARDS is 3 million cases annually, with approximately 200,000 cases in the U.S., and there are no approved treatments for ARDS . The company has paused most development initiatives for NoveCite to prioritize LYMPHIR and its other product candidates .

For the fiscal year ended September 30, 2025, Citius Pharmaceuticals reported no revenues . The company incurred a net loss of $39,740,269 , compared to a net loss of $39,425,839 in the prior year . Operating expenses totaled $38,525,608 . Research and development expenses were $9,156,474 , general and administrative expenses were $18,532,843 , and stock-based compensation was $10,836,291 . The company had an operating loss of $38,525,608 . Interest income was $110,081 , and interest expense was $267,782 . Income tax expense was $1,056,960 . Net cash used in operating activities was $26,552,738 . As of September 30, 2025, cash and cash equivalents were $4,252,290 , total current liabilities were $44,914,740 , and the accumulated deficit was $238,804,129 .

Year-over-year, the net loss increased by $314,430 . Research and development expenses decreased by $2,750,127 , primarily due to decreased costs for Mino-Lok following the completion of its Phase 3 trial and lower costs for Halo-Lido after its Phase 2 study completion . R&D costs for LYMPHIR, however, increased by $3,209,611 due to expenses for a drug substance batch needed for pre-license inspection . General and administrative expenses increased by $283,441 , mainly due to higher costs for pre-launch commercial activities for LYMPHIR . Stock-based compensation expense decreased by $1,003,387 . Interest income decreased from $758,000 in 2024 to $110,081 in 2025 .

During the reported period, Citius Oncology launched LYMPHIR in December 2025 following its FDA approval in August 2024 . The company completed patient enrollment for the Mino-Lok Phase 3 trial in late December 2023 and announced positive topline results in May 2024 . In November 2024, a Type C meeting with the FDA provided a pathway for a future New Drug Application (NDA) submission for Mino-Lok . For Halo-Lido, positive results from the Phase 2b study were announced in June 2023, and a Phase 2 meeting with the FDA was held in April 2024 to discuss the go-forward path . Citius Pharma also executed a 1-for-25 reverse stock split effective November 25, 2024 .

Business Outlook & Financial Sufficiency

Citius Pharmaceuticals expects to incur additional expenses in the future as it continues to develop its product candidates, including seeking regulatory approval and protecting its intellectual property . The company anticipates that research and development expenses will continue to decrease in fiscal 2026 as it focuses on the commercialization of LYMPHIR and has completed the Phase 3 trial for Mino-Lok .

A major growth area for the company is the commercialization of LYMPHIR, which launched in December 2025 . Citius Oncology, the majority-owned subsidiary responsible for LYMPHIR, has established initial sales and marketing capabilities by contracting with a large third-party commercial sales and marketing organization . This includes a dedicated field force and marketing programs tailored for physicians and patients . Distribution agreements have been finalized with Cardinal Health, Cencora, and McKesson Corporation . Additionally, Citius Oncology has partnered with EVERSANA for integrated pre- and post-launch services, including medical information, pharmacovigilance, revenue cycle management, and data analytics . LYMPHIR's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines with a Category 2A recommendation in September 2024 is expected to assist in obtaining coverage and reimbursement from the Centers for Medicare and Medicaid Services (CMS) . In February 2025, LYMPHIR was assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J9161) by CMS, which is a key step in facilitating reimbursement and patient access . Citius Oncology is also engaging with regional distribution partners for Named Patient Programs (NPPs) in Europe, South America, and the Middle East, having entered an exclusive distribution agreement with Integris Pharma S.A. covering Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro, and North Macedonia .

For Mino-Lok, the company held a Type C meeting with the FDA in November 2024, which provided clear, constructive, and actionable guidance for a future New Drug Application (NDA) submission . The company continues to engage with the FDA to define the regulatory path forward . Mino-Lok has received Qualified Infectious Disease Product (QIDP) designation, which provides an additional five years of market exclusivity, potentially combining with three years of exclusivity for new strength and formulation to result in a total of eight years of market exclusivity, regardless of patent protection . The company believes there is no FDA-approved alternative currently available to salvage infected indwelling central venous catheters .

Regarding Halo-Lido, Citius Pharma had a Phase 2 meeting with the FDA in April 2024 to discuss the go-forward path for the program, and ongoing engagement with the FDA is planned for the next steps of development . The company is actively pursuing intellectual property protections for its proprietary Patient Reported Outcome (PRO) instrument, Hemorrhoid Quality of Life Index (HQLI), and has filed patent applications on its CITI-002 formulations . If approved, Halo-Lido would be the only prescription product for hemorrhoids with proven safety and efficacy data, potentially qualifying for three years of market exclusivity for its dosage strength and formulation .

The company expects to finance its operations through a combination of equity offerings, debt financings, collaborations, or other strategic transactions . As of September 30, 2025, the company had outstanding milestone payment obligations of $2,900,000 to Eisai and $19,750,000 to Dr. Reddy's . Additionally, there are minimum purchase commitments under manufacturing and supply agreements totaling approximately $16.2 million for drug substance (with $8.5 million for calendar year 2025, $5.3 million for 2026, and $2.4 million for 2026 pass-throughs and consumable components) , and approximately $4.9 million for finished drug product completion and packaging ($1.2 million in 2025, $1.9 million in 2026, and $1.8 million in 2027) . The company expects to have sufficient funds to continue operations through March 2026, after accounting for a $6.0 million capital raise in October 2025 and an $18.0 million capital raise by Citius Oncology in December 2025 . Additional capital will be needed to support operations beyond March 2026 .

Management Sentiments & Priorities

Management's overall tone emphasizes the company's transition to a commercial entity with the launch of LYMPHIR in December 2025, while continuing to advance its late-stage pipeline. They highlight the strategic focus on first-in-class critical care products with lower development risk, often through new formulations of previously approved drugs. Management explicitly states that the company expects to have sufficient funds to continue operations through March 2026 , after taking into account a $6.0 million capital raise in October 2025 and an $18.0 million capital raise by Citius Oncology in December 2025 . However, they acknowledge the need to raise additional capital to support operations beyond March 2026 . Key strategic priorities include the successful commercialization of LYMPHIR, advancing the regulatory path for Mino-Lok towards an NDA submission, and exploring strategic or financial partnerships for Halo-Lido. Management also notes the pausing of most development initiatives for NoveCite to prioritize LYMPHIR and other product candidates .

Risk Factors

Citius Pharmaceuticals faces substantial risks, including an explanatory paragraph in its independent registered public accounting firm's report stating substantial doubt about its ability to continue as a going concern, with estimated sufficient capital only through March 2026 . The company requires substantial additional funding to support operations, commercialize LYMPHIR, and continue developing other product candidates, which may not be available on acceptable terms or at all . There is a history of net losses, with $39,740,269 and $39,425,839 for the years ended September 30, 2025 and 2024, respectively, and an accumulated deficit of $238,804,129 as of September 30, 2025. The company has outstanding liabilities of $38.4 million and commitments of $22.7 million to third parties for LYMPHIR licensing, supply, and other costs, which if unpaid, could interrupt commercialization or lead to loss of licensing rights . The ongoing exploration of strategic alternatives may not result in completed transactions, and failure to secure additional financing or strategic partners could force delays, reductions, or termination of commercialization efforts and business operations . Both Citius Pharma and Citius Oncology are heavily dependent on the launch and commercial success of LYMPHIR, which has an unproven business strategy and limited operating history . The company relies exclusively on third parties for formulation and manufacturing, and failure to meet contractual obligations, including timely payments, could result in loss of necessary third-party support . The markets are highly competitive, with many larger, well-financed companies, and new entrants or established companies may develop more effective or less costly products . Regulatory approval processes are complex, unpredictable, and costly, with no assurance of timely approval or market acceptance for product candidates . Even with Fast Track designation for Mino-Lok, a faster development or approval process is not guaranteed . Healthcare reform measures, including price controls and reimbursement restrictions, could hinder commercial success and reduce revenues . The company does not own Citius Oncology or NoveCite outright, meaning benefits from commercialization and development will be shared with other stockholders, and future equity issuances could further dilute ownership . The NoveCite product candidate, based on novel iPSC-derived cell technologies, faces uncertainties in regulatory approval, development time, cost, and ability to successfully initiate and complete clinical development .

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Overview
  3. [3] Item 1A, Risk Factors — Risks Related to Our Financial Position and Need for Additional Capital
  4. [4] Item 1, Business — Sales and Marketing
  5. [5] Item 1, Business — Overview
  6. [6] Item 1, Business — Citius Oncology and the Merger
  7. [7] Item 1, Business — Market Opportunity (LYMPHIR)
  8. [8] Item 1, Business — LYMPHIR TM (denileukin diftitox-cdxl)
  9. [9] Item 1, Business — Preliminary Results (Pembrolizumab and LYMPHIR)
  10. [10] Item 1, Business — Mino-Lok ® Overview
  11. [11] Item 1, Business — Mino-Lok ® Overview
  12. [12] Item 1, Business — Phase 2b Results (Mino-Lok)
  13. [13] Item 1, Business — Phase 3 Trial (Mino-Lok)
  14. [14] Item 1, Business — Phase 3 Trial (Mino-Lok)
  15. [15] Item 1, Business — Market Opportunity (Mino-Lok)
  16. [16] Item 1, Business — Halo-Lido Overview
  17. [17] Item 1, Business — Market Opportunity (Halo-Lido)
  18. [18] Item 1, Business — CITI-002 Phase 2b Trial Results
  19. [19] Item 1, Business — Market Opportunity (Halo-Lido)
  20. [20] Item 1, Business — NoveCite Overview
  21. [21] Item 1, Business — NoveCite Overview
  22. [22] Item 1, Business — NoveCite Overview
  23. [23] Item 1, Business — Market Opportunity (NoveCite)
  24. [24] Item 1, Business — NoveCite Overview
  25. [25] Item 7, MD&A — Results of Operations
  26. [26] Item 7, MD&A — Net Loss
  27. [27] Item 7, MD&A — Net Loss
  28. [28] Item 7, MD&A — Results of Operations
  29. [29] Item 7, MD&A — Results of Operations
  30. [30] Item 7, MD&A — Results of Operations
  31. [31] Item 7, MD&A — Results of Operations
  32. [32] Item 7, MD&A — Results of Operations
  33. [33] Item 7, MD&A — Results of Operations
  34. [34] Item 7, MD&A — Results of Operations
  35. [35] Item 7, MD&A — Results of Operations
  36. [36] Item 7, MD&A — Liquidity and Working Capital
  37. [37] Item 7, MD&A — Liquidity and Working Capital
  38. [38] Item 7, MD&A — Liquidity and Working Capital
  39. [39] Item 7, MD&A — Liquidity and Working Capital
  40. [40] Item 7, MD&A — Net Loss
  41. [41] Item 7, MD&A — Research and Development Expenses
  42. [42] Item 7, MD&A — Research and Development Expenses
  43. [43] Item 7, MD&A — Research and Development Expenses
  44. [44] Item 7, MD&A — Research and Development Expenses
  45. [45] Item 7, MD&A — Research and Development Expenses
  46. [46] Item 7, MD&A — General and Administrative Expenses
  47. [47] Item 7, MD&A — General and Administrative Expenses
  48. [48] Item 7, MD&A — Stock-based Compensation Expense
  49. [49] Item 7, MD&A — Other Income (Expense)
  50. [50] Item 1, Business — Regulatory Development (LYMPHIR)
  51. [51] Item 1, Business — Phase 3 Trial (Mino-Lok)
  52. [52] Item 1, Business — Phase 3 Trial (Mino-Lok)
  53. [53] Item 1, Business — CITI-002 Phase 2b Trial Results
  54. [54] Item 7, MD&A — Reverse Stock Split
  55. [55] Item 1A, Risk Factors — Risks Related to Our Financial Position and Need for Additional Capital
  56. [56] Item 7, MD&A — Research and Development Expenses
  57. [57] Item 1, Business — Overview
  58. [58] Item 1, Business — LYMPHIR Sales and Marketing
  59. [59] Item 1, Business — LYMPHIR Sales and Marketing
  60. [60] Item 1, Business — LYMPHIR Sales and Marketing
  61. [61] Item 1, Business — LYMPHIR Sales and Marketing
  62. [62] Item 1, Business — LYMPHIR Sales and Marketing
  63. [63] Item 1, Business — LYMPHIR Sales and Marketing
  64. [64] Item 1, Business — LYMPHIR Sales and Marketing
  65. [65] Item 1, Business — Phase 3 Trial (Mino-Lok)
  66. [66] Item 1, Business — Phase 3 Trial (Mino-Lok)
  67. [67] Item 1, Business — Mino-Lok Intellectual Property
  68. [68] Item 1, Business — Phase 3 Trial (Mino-Lok)
  69. [69] Item 1, Business — CITI-002 Phase 2b Trial Results
  70. [70] Item 1, Business — CITI-002 Phase 2b Trial Results
  71. [71] Item 1, Business — Market Exclusivity (Halo-Lido)
  72. [72] Item 1A, Risk Factors — We require substantial additional funding in the near future to support our operations, complete the commercialization of LYMPHIR, and continue the development of our other product candidates, which capital may not be available on acceptable terms, or at all.
  73. [73] Item 7, MD&A — Financing Activities
  74. [74] Item 7, MD&A — Financing Activities
  75. [75] Item 7, MD&A — Financing Activities
  76. [76] Item 7, MD&A — Liquidity and Capital Resources
  77. [77] Item 7, MD&A — Liquidity and Capital Resources
  78. [78] Item 1A, Risk Factors — Our independent registered public accounting firm’s report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern.
  79. [79] Item 1A, Risk Factors — We require substantial additional funding in the near future to support our operations, complete the commercialization of LYMPHIR, and continue the development of our other product candidates, which capital may not be available on acceptable terms, or at all.
  80. [80] Item 7, MD&A — Net Loss
  81. [81] Item 7, MD&A — Net Loss
  82. [82] Item 7, MD&A — Liquidity and Working Capital
  83. [83] Item 1A, Risk Factors — We have a history of net losses and expect to incur losses for the foreseeable future. We may never generate revenues or, if we are able to generate revenues, achieve profitability.
  84. [84] Item 1A, Risk Factors — Our and Citius Oncology’s ongoing explorations of alternative strategic paths may not result in entering into or completing transactions, when necessary, and the process of reviewing alternative strategic paths or their conclusion could adversely affect our stock price.
  85. [85] Item 1A, Risk Factors — We are primarily a commercial and late-stage development company with an unproven business strategy and may never achieve commercialization of all our therapeutic product candidates or profitability.
  86. [86] Item 1A, Risk Factors — We rely exclusively on third parties to formulate and manufacture our product candidates. Our failure to abide by our contractual obligations with these third parties, including timely payment, could result in a delay or the loss of necessary third-party support.
  87. [87] Item 1A, Risk Factors — The markets in which we operate are highly competitive and we might be unable to compete successfully against new entrants or established companies.
  88. [88] Item 1A, Risk Factors — We face significant risks in our product candidate development efforts.
  89. [89] Item 1A, Risk Factors — Any fast track designation or grant of priority review status by the FDA may not actually lead to a faster development or regulatory review or approval process, nor will it assure FDA approval of our product candidates. Additionally, our product candidates may treat indications that do not qualify for priority review vouchers.
  90. [90] Item 1A, Risk Factors — Healthcare reform measures could hinder or prevent our product candidates’ commercial success.
  91. [91] Item 1A, Risk Factors — We do not own Citius Oncology or NoveCite, Inc. outright and will share any benefits from the commercialization of LYMPHIR and the development of the NoveCite product candidate with the other stockholders.
  92. [92] Item 1A, Risk Factors — Because our NoveCite product candidate is based on novel technologies, it is difficult to predict the regulatory approval process and the time, the cost and our ability to successfully initiate, conduct and complete clinical development, and obtain the necessary regulatory and reimbursement approvals, required for commercialization of our NoveCite product candidate.
  93. [93] Item 7, MD&A — Liquidity and Capital Resources
  94. [94] Item 7, MD&A — Liquidity and Capital Resources
  95. [95] Item 7, MD&A — Liquidity and Capital Resources
  96. [96] Item 7, MD&A — Liquidity and Capital Resources
  97. [97] Item 1, Business — NoveCite Overview

Analysis on 5/22/2026